In a previous study, the researchers showed that PSA scores can impact both doctor and patient behavior, leading to biopsy ...

Tumor heterogeneity, which refers to variations in the cellular and genetic components between cancer cells within a tumor, can complicate the determination of optimal treatment approaches for ...

Decision making is evidence based and must be shielded from lobbying The NHS draft recommendation against routine prostate ...

Prostate cancer (PCa) represents a highly heterogeneous disease that requires tools to assess oncologic risk and guide patient management and treatment planning. Current models are based on various ...

GG1 prostate cancer can have heterogeneous outcomes, with some patients having intermediate- or high-risk disease, challenging the notion of GG1 as uniformly low-risk. Removing the cancer label for ...

University Hospitals Seidman Cancer Center researchers have developed a tool that could identify metastatic prostate cancer ...

Recent advances in cancer biology have revealed that refractory malignancies, such as castration-resistant prostate cancer, pancreatic ductal ...

Tests do not consistently influence risk classification or treatment decisions; authors call for well-designed trials on role of GC tests in newly diagnosed PCa. (HealthDay News) — For patients with ...

You may have heard the saying ‘cancer is not one disease, but many diseases,’ referring to the fact that different cancers—even from the same tissue of origin—can be radically different from one ...